ARTICLE | Clinical News

Tecfidera dimethyl fumarate regulatory update

December 8, 2014 8:00 AM UTC

Germany’s Federal Joint Committee (G-BA) issued a final benefit assessment that said Tecfidera dimethyl fumarate from Biogen offers no additional benefit over interferon beta-1a to treat relapsing-remitting multiple sclerosis (RRMS).The assessment is in line with a preliminary benefit assessment from Germany’s Institute for Quality and Efficiency in Healthcare (IQWiG) (see BioCentury, Aug. 11). Biogen said that the G-BA’s decision “forms the basis for negotiating a final price” of Tecfidera with Germany’s Federal Association of Statutory Health Insurance Funds. ...